Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02829372 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study of Single Agent GBR 1302 in Subjects With HER2 Positive Cancers
A Phase 1 study, sponsored by Ichnos Sciences.
- Terminated
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT02829372: Clinical Trial Phase 1 study, sponsored by Ichnos Sciences.
NCT02829372 is a Phase 1 study that was terminated before completion, run by Ichnos Sciences. The registered enrollment target is 36 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (40% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02829372, a Phase 1 study, was terminated before completion, sponsored by Ichnos Sciences.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety profile and maximum tolerable dose (MTD) of GBR 1302 monotherapy in subjects with HER2 positive cancers
Primary Outcome
Number of DLTs (dose limiting toxicities) after the first two administrations of study drug (i.e. Cycle 1) in each cohort
Interventions
- DRUG CD3/HER2 bispecific monoclonal antibody
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2016-05 |
| Est. Completion | 2019-05 |
| Phase | Phase 1 |
Why NCT02829372 stopped before completion
NCT02829372 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (40% lower).
The record links to 0 conditions, and to 1 intervention - of which CD3/HER2 bispecific monoclonal antibody is the first listed.
NCT02829372 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02829372 about?
NCT02829372 is a clinical study titled "Phase 1 Study of Single Agent GBR 1302 in Subjects With HER2 Positive Cancers". The purpose of this study is to determine the safety profile and maximum tolerable dose (MTD) of GBR 1302 monotherapy in subjects with HER2 positive cancers
What is the current status of trial NCT02829372?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2016-05. Estimated completion is 2019-05.
What interventions are being tested in trial NCT02829372?
The interventions under investigation include: CD3/HER2 bispecific monoclonal antibody (DRUG).
Who is sponsoring clinical trial NCT02829372?
This trial is sponsored by Ichnos Sciences, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02829372's enrollment target sits among peer trials
36 1210th of 2000 higher than 743 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia